ArticleBlood cancer discovery2020
Mutational landscape and patterns of clonal evolution in relapsed pediatric acute lymphoblastic leukemia.
Open access · greenAbstract read
In one paragraph
Article in Blood cancer discovery, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 101 papers.
0numbers the graph read from it
0cells of the map it votes in
101citing papers in PubMed
18.2field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
101 citing papers in PubMed, 148 citations in OpenAlex.
- Genomic Characterization of RTK-RAS Pathway Alterations in Juvenile Myelomonocytic Leukemia Through Whole-Exome Sequencing.Medical sciences (Basel, Switzerland) · 2026Article
- A genomic and epigenomic lens into the biology of acute lymphoblastic leukaemia.Nature reviews. Cancer · 2026Review
- Dual epitope anti-LILRB4 synthetic T-cell receptor and antigen receptor (STAR)-T-cell therapy for relapsed/refractory acute myeloid leukemia.Signal transduction and targeted therapy · 2026Article
- Chemotherapy-driven expression of WNT ligands in bone marrow stromal cells contributes to chemoresistance in acute lymphoblastic leukaemia.British journal of haematology · 2026Article
- Article
- Tumor Genomics and Liquid Biopsy in Cancer Biology: From Static Snapshots to Dynamic Measurements.Biomolecules · 2026Article
- Glycosylation converts CD24 from a developmental marker into a glyco-immune checkpoint in B-cell acute lymphoblastic leukemia.Frontiers in immunology · 2026Review
- Relapse in childhood B-cell precursor acute lymphoblastic leukemia: insights from transcriptomic signatures of diagnostic bone marrow.Frontiers in oncology · 2026Review
- Complex genotype-phenotype relationships shape the response to treatment of down syndrome childhood acute lymphoblastic leukaemia.Scientific reports · 2025Article
- The genomic landscape of relapsed infant and childhood KMT2A-rearranged acute leukemia.Nature communications · 2025Article
- Insights into the Prognostic Value of Telomere Length in Childhood Acute Lymphoblastic Leukemia.Life (Basel, Switzerland) · 2025Article
- Treatment-related mutagenic processes in acute lymphoblastic leukemia.Haematologica · 2025Review
- Article
- Article
- Multipotent lineage potential in B cell acute lymphoblastic leukemia is associated with distinct cellular origins and clinical features.Nature cancer · 2025Article
- Application of Optical Genome Mapping for the Diagnosis and Risk Stratification of Myeloid and Lymphoid Malignancies.International journal of molecular sciences · 2025Article
- Review
- CREBBP inactivation sensitizes B cell acute lymphoblastic leukemia to ferroptotic cell death upon BCL2 inhibition.Nature communications · 2025Article
- Genetic evolution and relapse-associated mutations in adult T-cell acute lymphoblastic leukemia patients treated in PETHEMA trials.HemaSphere · 2025Article
- Review
41 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
43 authors at 5 institutions in 3 countries.
Esmé Waanders *Department of Pathology, St. Jude Children's Research Hospital, Memphis, Tennessee.ORCID 0000-0002-2466-953X
Zhaohui Gu *Department of Pathology, St. Jude Children's Research Hospital, Memphis, Tennessee.
Stephanie M Dobson *Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
Željko Antić *Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.
Jeremy Chase CrawfordDepartment of Immunology, St. Jude Children's Research Hospital, Memphis, Tennessee.
Xiaotu MaDepartment of Computational Biology, St. Jude Children's Research Hospital, Memphis, Tennessee.
Michael N EdmonsonDepartment of Computational Biology, St. Jude Children's Research Hospital, Memphis, Tennessee.ORCID 0000-0003-0339-700X
Debbie Payne-TurnerDepartment of Pathology, St. Jude Children's Research Hospital, Memphis, Tennessee.
Maartje van de VorstDepartment of Human Genetics, Radboud University Medical Center, Radboud Institute for Molecular Life Sciences, Nijmegen, the Netherlands.
Marjolijn C J JongmansPrincess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.
Irina McGuireDepartment of Information Services, St. Jude Children's Research Hospital, Memphis, Tennessee.
Xin ZhouDepartment of Computational Biology, St. Jude Children's Research Hospital, Memphis, Tennessee.
Jian WangDepartment of Computational Biology, St. Jude Children's Research Hospital, Memphis, Tennessee.
Lei ShiDepartment of Biostatistics, St. Jude Children's Research Hospital, Memphis, Tennessee.
Stanley PoundsDepartment of Biostatistics, St. Jude Children's Research Hospital, Memphis, Tennessee.
Deqing PeiDepartment of Biostatistics, St. Jude Children's Research Hospital, Memphis, Tennessee.
Cheng ChengDepartment of Biostatistics, St. Jude Children's Research Hospital, Memphis, Tennessee.
Guangchun SongDepartment of Pathology, St. Jude Children's Research Hospital, Memphis, Tennessee.
Yiping FanDepartment of Computational Biology, St. Jude Children's Research Hospital, Memphis, Tennessee.
Ying ShaoDepartment of Computational Biology, St. Jude Children's Research Hospital, Memphis, Tennessee.ORCID 0000-0002-0390-3315
Michael RuschDepartment of Computational Biology, St. Jude Children's Research Hospital, Memphis, Tennessee.ORCID 0000-0002-5363-1848
Kelly McCastlainDepartment of Pathology, St. Jude Children's Research Hospital, Memphis, Tennessee.ORCID 0000-0001-7868-3049
Jiangyan YuPrincess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.
Ruben van BoxtelPrincess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.
Francis BlokzijlOncode Institute, University Medical Center Utrecht, Utrecht, the Netherlands.
Ilaria IacobucciDepartment of Pathology, St. Jude Children's Research Hospital, Memphis, Tennessee.
Kathryn G RobertsDepartment of Pathology, St. Jude Children's Research Hospital, Memphis, Tennessee.
Ji WenDepartment of Pathology, St. Jude Children's Research Hospital, Memphis, Tennessee.
Gang WuDepartment of Computational Biology, St. Jude Children's Research Hospital, Memphis, Tennessee.
Jing MaDepartment of Pathology, St. Jude Children's Research Hospital, Memphis, Tennessee.
John EastonDepartment of Computational Biology, St. Jude Children's Research Hospital, Memphis, Tennessee.
Geoffrey NealeThe Hartwell Center for Bioinformatics and Biotechnology, St. Jude Children's Research Hospital, Memphis, Tennessee.ORCID 0000-0003-3776-0858
Scott R OlsenThe Hartwell Center for Bioinformatics and Biotechnology, St. Jude Children's Research Hospital, Memphis, Tennessee.
Kim E NicholsDepartment of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee.
Ching-Hon PuiDepartment of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee.
Jinghui ZhangDepartment of Computational Biology, St. Jude Children's Research Hospital, Memphis, Tennessee.
William E EvansDepartment of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee.
Mary V RellingDepartment of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee.
Jun J YangDepartment of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee.
Paul G ThomasDepartment of Immunology, St. Jude Children's Research Hospital, Memphis, Tennessee.ORCID 0000-0001-7955-0256
John E DickPrincess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.ORCID 0000-0002-9527-8317
Roland P Kuiper *Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.
Charles G Mullighan *Department of Pathology, St. Jude Children's Research Hospital, Memphis, Tennessee. charles.mullighan@stjude.org.ORCID 0000-0002-1871-1850
St. Jude Children's Research Hospital · USPrincess Máxima Center · NLUniversity of Toronto · CAUtrecht University · NLRadboud University Nijmegen · NL
Funding
Viral Vector Technology (VVTSR)P30CA021765 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI Heather M Brandt · 1985 to 2026
$166.9MCPML - Project 3: Genome-wide Studies of Adverse EffectsP50GM115279 · NIGMS · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI LOH, MIGNON LEE-CHEUN, RELLING, MARY V · 2015 to 2019
$15.1MTranslating genomic discoveries to improved outcomes for high risk acute leukemiaR35CA197695 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI Charles G Mullighan · 2017 to 2026
$11.4MPharmacogenomics of Childhood Leukemia ALLR01CA036401 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI EVANS, WILLIAM E · 1985 to 2019
$3.6MCharacterization of novel subtypes in B progenitor acute lymphoblastic leukemiaR00CA241297 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI GU, ZHAOHUI · 2020 to 2022
$747kCharacterization of novel subtypes in B progenitor acute lymphoblastic leukemiaK99CA241297 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI GU, ZHAOHUI · 2019 to 2019
$90kNCI NIH HHS K99 CA241297NCI NIH HHS P30 CA021765NCI NIH HHS R00 CA241297NCI NIH HHS R01 CA036401NCI NIH HHS R35 CA197695NIGMS NIH HHS P50 GM115279
Abstract
Relapse of acute lymphoblastic leukemia (ALL) remains a leading cause of childhood death. Prior studies have shown clonal mutations at relapse often arise from relapse-fated subclones that exist at diagnosis. However, the genomic landscape, evolutionary trajectories and mutational mechanisms driving relapse are incompletely understood. In an analysis of 92 cases of relapsed childhood ALL, incorporating multimodal DNA and RNA sequencing, deep digital mutational tracking and xenografting to formally define clonal structure, we identify 50 significant targets of mutation with distinct patterns of mutational acquisition or enrichment.
Indexed as
Clonal EvolutionPrecursor Cell Lymphoblastic Leukemia-LymphomaChildGenomicsHumansMutationRecurrenceacute lymphoblastic leukemiaclonal evolutiongenomicshypermutationneoepitopesrelapse
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.